Corvus Pharmaceuticals, Inc.
CRVS
$7.07
-$0.76-9.66%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.16M | -8.00M | 15.19M | -12.11M | -40.22M |
| Total Depreciation and Amortization | 28.00K | 29.00K | 22.00K | 20.00K | 21.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.11M | -701.00K | -23.63M | 5.09M | 33.74M |
| Change in Net Operating Assets | -550.00K | 2.89M | 152.00K | -1.46M | 138.00K |
| Cash from Operations | -9.57M | -5.78M | -8.26M | -8.47M | -6.32M |
| Capital Expenditure | 0.00 | -113.00K | -36.00K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 5.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.62M | -20.19M | 4.28M | -6.09M | -3.89M |
| Cash from Investing | -2.62M | -20.30M | 4.24M | -6.08M | -3.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 360.00K | 35.77M | 279.00K | 18.61M | 50.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | 360.00K | 35.77M | 279.00K | 18.61M | 50.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.82M | 9.69M | -3.74M | 4.06M | -10.16M |